Serum alpha klotho levels in Parkinson's Disease

Neurol Sci. 2025 Feb;46(2):743-749. doi: 10.1007/s10072-024-07809-w. Epub 2024 Oct 29.

Abstract

Purpose: Parkinson's Disease (PD), a neurodegenerative disorder, is associated with substantial morbidity. α-Klotho, an anti-aging protein known for its neuroprotective properties, has gained attention. This study aims to assess serum levels of α-Klotho in PD patients.

Methods: This study is a cross-sectional case-control study. PD was diagnosed according to UK Parkinson Disease Society Brain Bank criteria. Serum α-Klotho level was measured using a commercially available enzyme-linked immunosorbent assay.

Results: Of the 314 participants in the study, 157 were patients with PD and 157 were controls. Lower levels of α-Klotho were observed in PD (0.85 nmol/L) in comparison to the controls (1.47 nmol/L, p < 0.001). α-Klotho levels were also significantly lower among PD patients with dementia compared to PD patients without dementia. In logistic regression analysis, α-Klotho (OR: 0.04, p < 0.001) demonstrated a significant relationship between PD. A significant correlation was identified between α-Klotho levels and Mini-Mental State Examination scores in PD patients. The sensitivity and the specifity of α-Klotho were 90% and 65% for predicting PD.

Conclusions: Our findings suggest that α-klotho could potentially serve as a biomarker. However additional studies are needed to confirm our findings.

Keywords: Dementia; Older individuals; Parkinson’s disease; α-Klotho protein.

MeSH terms

  • Aged
  • Biomarkers / blood
  • Case-Control Studies
  • Cross-Sectional Studies
  • Dementia / blood
  • Female
  • Glucuronidase* / blood
  • Humans
  • Klotho Proteins
  • Male
  • Middle Aged
  • Parkinson Disease* / blood
  • Parkinson Disease* / complications
  • Parkinson Disease* / diagnosis

Substances

  • Klotho Proteins
  • Glucuronidase
  • Biomarkers
  • KL protein, human